PET and PET-CT imaging of gynecological malignancies: Present role and future promise

Expert Review of Anticancer Therapy

Volumn 9, Issue 1, 2009, Pages 75-96

  Basu, Sandip ^a   Li, Geming ^b   Alavi, Abass ^b  

^a TATA MEMORIAL HOSPITAL   (India)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

18F fluoroestradiol; Carbon 11 methionine; Carcinoma of the fallopian tube; Carcinoma of the vulva; Cervical carcinoma; CT; Endometrial carcinoma; FDG PET; Gynecological malignancy; MRI; Non FDG PET tracer; Ovarian carcinoma; PET; PET CT; Vaginal carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; CHOLINE CARBON 11; CISPLATIN; CONTRAST MEDIUM; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTRADIOL FLUORINE 18; FLUORODEOXYGLUCOSE; METHIONINE CARBON 11; PREDNISONE; RITUXIMAB; TAMOXIFEN; UNCLASSIFIED DRUG; VINCRISTINE;

ADVANCED CANCER; B CELL LYMPHOMA; BRACHYTHERAPY; CANCER DIAGNOSIS; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CLINICAL EVALUATION; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE CLASSIFICATION; DOSE RESPONSE; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FALSE POSITIVE RESULT; GYNECOLOGIC CANCER; HEALTH CARE COST; HISTOPATHOLOGY; HUMAN; HYSTERECTOMY; LARGE CELL LYMPHOMA; LUNG CARCINOMA; LYMPHADENECTOMY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARIECTOMY; OVARY CANCER; OVARY CARCINOMA; OVARY INFLAMMATION; OVARY LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RELIABILITY; REVIEW; SALPHINGOOPHORITIS; SENSITIVITY AND SPECIFICITY; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR VOLUME; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERINE TUBE CARCINOMA; UTERUS CANCER; VAGINA CANCER; VAGINA CARCINOMA; VULVA CANCER; VULVA CARCINOMA; WHOLE BODY PET; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FEMALE GENITAL TRACT TUMOR; PATHOLOGY; RADIOGRAPHY; SCINTISCANNING;

FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 61449442444     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.9.1.75     Document Type: Review

References (95)

1. Long HJ 3rd. Management of metastatic cervical cancer: review of the literature. J. Clin. Oncol. 25(20), 2966-2974 (2007).
2. Pazdur R, Coia LR, Hoskins WJ, Wagman LD (Eds). Cancer Management: a Multidisciplinary Approach (4th Edition). PRR Inc. NY, USA 361-430 (1999).
3. Syrjänen K. Mechanisms and predictors of high-risk human papillomavirus (HPV) clearance in the uterine cervix. Eur. J. Gynaecol. Oncol. 28(5), 337-351.
4. Alvarez-Salas LM, DiPaolo JA. Molecular approaches to cervical cancer therapy. Curr. Drug Discov. Technol. 4(3), 208-219 (2007).
5. Koyama T, Tamai K, Togashi K. Staging of carcinoma of the uterine cervix and endometrium. Eur. Radiol. 17(8), 2009-2019 (2007).
6. Pecorelli S, Ngan HYS, Hacker NF (Eds). Staging Classifications and Clinical Practice Guidelines for Gynaecological Cancers. A Collaboration Between FIGO and IGCS. (3rd Edition). FIGO, London, UK (2006).
7. Heller PB, Malfetano JH, Bundy BN, Barnhill DR, Okagaki T. Clinicalpathologic study of stage IIB, III, and IVA carcinoma of the cervix: extended diagnostic evaluation for para-aortic node metastasis - a Gynecologic Oncology Group study. Gynecol. Oncol. 38(3), 425-430 (1990).
8. Hricak H, Lacey CG, Sandles LG, Chang YC, Winkler ML, Stern JL. Invasive cervical carcinoma: comparison of MR imaging and surgical findings. Radiology 166, 623-631 (1988).
9. Delgado G, Bundy B, Zaino R, Sevin BU, Creasman WT, Major F. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol. Oncol. 38(3), 352-357 (1990).
10. Sevin BU, Lu Y, Bloch DA, Nadji M, Koechli OR, Averette HE. Surgically defined prognostic parameters in patients with early cervical carcinoma. A multivariate survival tree analysis. Cancer 78(7), 1438-1446 (1996).
11. Sahdev A, Sohaib SA, Wenaden AE, Shepherd JH, Reznek RH. The performance of magnetic resonance imaging in early cervical carcinoma: a longterm experience. Int. J. Gynecol. Cancer 17(3), 629-636 (2007).
12. 18FDG PET imaging in the management of cervical cancer. Gynecol. Oncol. 87 (1), 90-97 (2002).
13. Grigsby PW, Dehdashti F, Siegel BA. FDG-PET Evaluation of carcinoma of the cervix. Clin. Positron Imaging 2(2), 105-109 (1999).
14. Grigsby PW, Siegel BA, Dehdashti F. Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J. Clin. Oncol. 19(17), 3745-3749 (2001).
15. Grigsby PW, Siegel BA, Dehdashti F, Mutch DG. Posttherapy surveillance monitoring of cervical cancer by FDGPET. Int. J. Radiat. Oncol. Biol. Phys. 55(4), 907-913 (2003).
16. 18F]fluoro-d-glucose for evaluating local and distant disease in patients with cervical cancer. Mol. Imaging Biol. 6, 55-62 (2004).
17. Tran BN, Grigsby PW, Dehdashti F, Herzog TJ, Siegel BA. Occult supraclavicular lymph node metastasis identified by FDG-PET in patients with carcinoma of the uterine cervix. Gynecol. Oncol. 90, 572-576 (2003).
18. Hope AJ, Saha P, Grigsby PW. FDG-PET in carcinoma of the uterine cervix with endometrial extension. Cancer 106(1), 196-200 (2006).
19. Wright JD, Dehdashti F, Herzog TJ et al. Preoperative lymph node staging of early-stage cervical carcinoma by [18F]-fluoro-2-deoxy-d-glucose-positron emission tomography. Cancer 104(11), 2484-2491 (2005).
20. Sironi S, Buda A, Picchio M et al. Lymph node metastasis in patients with clinical early-stage cervical cancer: detection with integrated FDG PET/CT. Radiology 238(1), 272-279 (2006).
21. Bjurberg M, Kjellén E, Ohlsson T, Ridderheim M, Brun E. FDG-PET in cervical cancer: staging, re-staging and follow-up. Acta Obstet. Gynecol. Scand. 86(11), 1385-1391 (2007).
22. Havrilesky LJ, Kulasingam SL, Matchar DB, Myers ER. FDG-PET for management of cervical and ovarian cancer. Gynecol. Oncol. 97(1), 183-191 (2005).
23. Kerr IG, Manji MF, Powe J, Bakheet S, Al Suhaibani H, Subhi J. Positron emission tomography for the evaluation of metastases in patients with carcinoma of the cervix: a retrospective review. Gynecol. Oncol. 81(3), 477-480 (2001).
24. Yen TC, See LC, Lai CH et al. Standardized uptake value in para-aortic lymph nodes is a significant prognostic factor in patients with primary advanced squamous cervical cancer. Eur. J. Nucl. Med. Mol. Imaging 35(3), 493-501. (2008).
25. Kidd EA, Siegel BA, Dehdashti F, Grigsby PW. The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer 110(8), 1738-1744 (2007).
26. Xue F, Lin LL, Dehdashti F, Miller TR, Siegel BA, Grigsby PW. F-18 fluorodeoxyglucose uptake in primary cervical cancer as an indicator of prognosis after radiation therapy. Gynecol. Oncol. 101(1), 147-151 (2006).
27. 18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression. J. Nucl. Med. 45(1), 22-29 (2004).
28. Singh AK, Grigsby PW, Dehdashti F, Herzog TJ, Siegel BA. FDG-PET lymph node staging and survival of patients with FIGO stage IIIb cervical carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 56(2), 489-493 (2003).
29. Lin LL, Yang Z, Mutic S, Miller TR, Grigsby PW. FDG-PET imaging for the assessment of physiologic volume response during radiotherapy in cervix cancer. Int. J. Radiat. Oncol. Biol. Phys. 65(1), 177-181 (2006).
30. 18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J. Clin. Oncol. 22(11), 2167-2171 (2004).
31. Lin LL, Mutic S, Malyapa RS et al. Sequential FDG-PET brachytherapy treatment planning in carcinoma of the cervix. Int. J. Radiat. Oncol. Biol. Phys. 63(5), 1494-1501 (2005).
32. Chang WC, Hung YC, Lin CC, Shen YY, Kao CH. Usefulness of FDG-PET to detect recurrent cervical cancer based on asymptomatically elevated tumor marker serum levels - a preliminary report. Cancer Invest. 22(2), 180-184 (2004).
33. Lapela M, Leskinen-Kallio S, Varpula M et al. Imaging of uterine carcinoma by carbon-11-methionine and PET. J. Nucl. Med. 35, 1618-1623 (1994).
34. Torizuka T, Kanno T, Futatsubashi M et al. Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18) F-FDG PET. J. Nucl. Med. 44, 1051-1056 (2003).
35. 60Cu-ATSM in cancer of the uterine cervix. J. Nucl. Med. 49(7), 1177-1182 (2008).
36. Nahhas WA. Ovarian cancer: current outlook on this deadly disease. Postgrad. Med. 102, 112-120 (1997).
37. Young RC, Fuks Z, Hoskins WJ. Cancer of the ovary. In: Cancer: Principles and Practice of Oncology (6th Edition). Devita VT, Hellman S, Rosenberg SA (Eds). JB Lippincott Co., PA, USA (2001).
38. 18F]FDG). Gynecol. Oncol. 51, 197-204 (1993).
39. Yoshida Y, Kurokawa T, Kawahara K et al. Incremental benefits of FDG positron emission tomography over CT alone for the preoperative staging of ovarian cancer. AJR Am. J. Roentgenol. 182, 227-233 (2004).
40. 18-F-FGD PET in ovarian carcinoma. Int. J. Gynecol. Cancer. 9, 117-122 (1999).
41. Römer W, Avril N, Dose J et al. [Metabolic characterization of ovarian tumors with positron-emission tomography and F-18 fluorodeoxyglucose]. Rofo 166(1), 62-68 (1997).
42. 18F-fluorodeoxyglucose PET in ovarian carcinoma: methodology and preliminary results]. Nuklearmedizin 36(7), 228-233 (1997).
43. Rieber A, Nussle K, Stöhr I et al. Preoperative diagnosis of ovarian tumors with MR imaging: comparison with transvaginal sonography, positron emission tomography, and histologic findings. AJR Am. J. Roentgenol. 177(1), 123-129 (2001).
44. Risum S, Högdall C, Loft A et al. The diagnostic value of PET/CT for primary ovarian cancer - a prospective study. Gynecol. Oncol. 105(1), 145-149 (2007).
45. Risum S, Høgdall C, Loft A et al. Prediction of suboptimal primary cytoreduction in primary ovarian cancer with combined positron emission tomography/computed tomography - a prospective study. Gynecol. Oncol. 108(2), 265-270 (2008).
46. Rose PG, Faulhaber P, Miraldi F, Abdul-Karim FW. Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy. Gynecol. Oncol. 82, 17-21 (2001).
47. Drieskens O, Stroobants S, Gysen M, Vandenbosch G, Mortelmans L, Vergote I. Positron emission tomography with FDG in the detection of peritoneal and retroperitoneal metastases of ovarian cancer. Gynecol. Obstet. Invest. 55, 130-134 (2003).
48. Gu P, Pan LL, Wu SQ, Sun L, Huang G. CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis. Eur. J. Radiol. DOI: 10.1016/j.ejrad.2008.02.019 (2008) (Epub ahead of print).
49. Murakami M, Miyamoto T, Iida T et al. Whole-body positron emission tomography and tumor marker CA125 for detection of recurrence in epithelial ovarian cancer. Int. J. Gynecol. Cancer 16(Suppl. 1), 99-107 (2006).
50. 18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. Eur. Radiol. 10(5), 761-767 (2000).
51. Nakamoto Y, Saga T, Ishimori T et al. Clinical value of positron emission tomography with FDG for recurrent ovarian cancer. AJR Am. J. Roentgenol. 176(6), 1449-1454 (2001).
52. Hauth EA, Antoch G, Stattaus J et al. Evaluation of integrated whole-body PET/CT in the detection of recurrent ovarian cancer. Eur. J. Radiol. 56(2), 263-268 (2005).
53. 18F-FDG-PET in the suspicion of recurrent ovarian carcinoma based on elevated tumor marker serum levels. Clin. Positron Imaging 3(6), 231-236 (2000).
54. 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer. Anticancer Res. 21(5), 3691-3694 (2001).
55. Torizuka T, Nobezawa S, Kanno T et al. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy-dglucose. Eur. J. Nucl. Med. Mol. Imaging 29(6), 797-803 (2002).
56. Cho SM, Ha HK, Byun JY et al. Usefulness of FDG PET for assessment early recurrent epithelial ovarian cancer. AJR Am. J. Roentgenol. 179(2), 391-395 (2002).
57. 18F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients. Eur. J. Surg. Oncol. 31(7), 792-797 (2005).
58. Simcock B, Neesham D, Quinn M, Drummond E, Milner A, Hicks RJ. The impact of PET/CT in the management of recurrent ovarian cancer. Gynecol. Oncol. 103(1), 271-276 (2006).
59. 18F]FDG PET/ CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings. Eur. J. Nucl. Med. Mol. Imaging 34(4), 480-486 (2007).
60. Mangili G, Picchio M, Sironi S et al. Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer. Eur. J. Nucl. Med. Mol. Imaging 34(5), 658-666 (2007).
61. Thrall MM, DeLoia JA, Gallion H, Avril N. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer. Gynecol. Oncol. 105(1), 17-22 (2007).
62. García-Velloso MJ, Jurado M, Ceamanos et al. Diagnostic accuracy of FDG PET in the follow-up of platinum-sensitive epithelial ovarian carcinoma. Eur. J. Nucl. Med. Mol. Imaging 34(9), 1396-1405 (2007).
63. Sebastian S, Lee SI, Horowitz NS et al. PET-CT vs. CT alone in ovarian cancer recurrence. Abdom. Imaging 33(1), 112-118 (2008).
64. Sheng XG, Zhang XL, Fu Z et al. [Value of positron emission tomography-CT imaging combined with continual detection of CA125 in serum for diagnosis of early asymptomatic recurrence of epithelial ovarian carcinoma]. Zhonghua Fu Chan Ke Za Zhi 42(7), 460-463 (2007).
65. Soussan M, Wartski M, Cherel P et al. Impact of FDG PET-CT imaging on the decision making in the biologic suspicion of ovarian carcinoma recurrence. Gynecol. Oncol. 108(1), 160-165 (2008).
66. Kim CK, Park BK, Choi JY, Kim BG, Han H. Detection of recurrent ovarian cancer at MRI: comparison with integrated PET/CT. J. Comput. Assist. Tomogr. 31(6), 868-875 (2007).
67. Zimny M, Siggelkow W, Schroder W et al. 2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer, Gynecol. Oncol. 83, 310-315 (2001).
68. Avril N, Sassen S, Schmalfeldt B et al. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J. Clin. Oncol. 23(30), 7445-7453 (2005).
69. Kurosaki H, Oriuchi N, Okazaki A et al. Prognostic value of FDG-PET in patients with ovarian carcinoma following surgical treatment. Ann. Nucl. Med. 20(3), 171-174 (2006).
70. Smith GT, Hubner KF, McDonald T, Thie JA. Cost analysis of FDG PET for managing patients with ovarian cancer. Clin. Positron Imaging 2, 63-70 (1999).
71. Marchand V, Graveleau J, Lanctin-Garcia C et al. A rare gynecological case of paraneoplastic cerebellar degeneration discovered by FDG-PET. Gynecol. Oncol. 105(2), 545-547 (2007).
72. 18F-FDG PET for staging and assessment of the therapeutic response. Ann. Nucl. Med. 20(2), 157-160 (2006).
73. Lapela M, Leskinen-Kallio S, Varpula M et al. Metabolic imaging of ovarian tumors with carbon-11-methionine: a PET study. J. Nucl. Med. 36(12), 2196-2200 (1995).
74. 18F-FDG PET in the post-therapy surveillance of endometrial carcinoma. Eur. J. Nucl. Med. Mol. Imaging 29(9), 1132-1139 (2002).
75. Saga T, Higashi T, Ishimori T et al. Clinical value of FDG-PET in the follow up of post-operative patients with endometrial cancer. Ann. Nucl. Med. 17(3), 197-203 (2003).
76. 18F-FDG PET in the management of endometrial cancer. Eur. J. Nucl. Med. Mol. Imaging 33(1), 36-44 (2006).
77. Suzuki R, Miyagi E, Takahashi N et al. Validity of positron emission tomography using fluoro-2-deoxyglucose for the preoperative evaluation of endometrial cancer. Int. J. Gynecol. Cancer 17(4), 890-896 (2007).
78. Park JY, Kim EN, Kim DY et al. Clinical impact of positron emission tomography or positron emission tomography/computed tomography in the posttherapy surveillance of endometrial carcinoma: evaluation of 88 patients. Int. J. Gynecol. Cancer DOI 10.1111/ j.1525-1438.2008.01197.x (2008) (Epub ahead of print).
79. Lapela M, Leskinen-Kallio S, Varpula M et al. Imaging of uterine carcinoma by carbon-11-methionine and PET. J. Nucl. Med. 35(10), 1618-1623 (1994).
80. Yoshida Y, Kurokawa T, Sawamura Y et al. The positron emission tomography with F18 17β-estradiol has the potential to benefit diagnosis and treatment of endometrial cancer. Gynecol. Oncol. 104(3), 764-766 (2007).
81. Cohen I, Beyth Y, Altaras MM et al. Estrogen and progesterone receptor expression in postmenopausal tamoxifenexposed endometrial pathologies. Gynecol. Oncol. 67, 8-15 (1997).
82. Wilder JL, Shajahan S, Khattar NH et al. Tamoxifen-associated malignant endometrial tumors: pathologic features and expression of hormone receptors estrogen-α, estrogen-β and progesterone: a case controlled study. Gynecol. Oncol. 92, 553-558 (2004).
83. Furr BJ, Nicholson RI. The pharmacology and clinical uses of tamoxifen. Pharmacol. Ther. 25, 127-205 (1984).
84. Fabian C, Sternson L, El-Serafi M, Cain L, Hearne E. Clinical pharmacology of tamoxifen in patients with breast cancer: correlation with clinical data. Cancer 48, 876-882 (1981).
85. Cohn DE, Dehdashti F, Gibb RK et al. Prospective evaluation of positron emission tomography for the detection of groin node metastases from vulvar cancer. Gynecol. Oncol. 85, 179-184 (2002).
86. Rocconi RP, Leath CA 3rd, Johnson WM 3rd, Barnes MN 3rd, Conner MG. Primary lung large cell carcinoma metastatic to the vulva: a case report and review of the literature. Gynecol. Oncol. 94(3), 829-831 (2004).
87. Freudenberg LS, Antoch G, Beyer T, Görges R, Debatin JF, Bockisch A. Diagnosis of labia metastasis by F-18 FDG PET and CT fusion imaging in sarcoma follow-up. Clin. Nucl. Med. 28(8), 636-637 (2003).
88. Lamoreaux WT, Grigsby PW, Dehdashti F et al. FDG-PET evaluation of vaginal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 62(3), 733-737 (2005).
89. Karlan BY, Hoh C, Tse N, Futoran R, Hawkins R, Glaspy J. Whole-body positron emission tomography with (fluorine-18)-2-deoxyglucose can detect metastatic carcinoma of the fallopian tube. Gynecol. Oncol. 49(3), 383-388 (1993).
90. Makhija S, Howden N, Edwards R, Kelley J, Townsend DW, Meltzer CC. Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma: a retrospective review. Gynecol. Oncol. 85(1), 53-58 (2002).
91. Patel PV Cohade C, Chin BB. PET-CT localizes previously undetectable metastatic lesions in recurrent fallopian tube carcinoma. Gynecol. Oncol. 87(3), 323-326 (2002).
92. Kumar R, Alavi A. PET imaging in gynecologic malignancies. Radiol. Clin. North Am. 42(6), 1155-1167 (2004).
93. Park JY, Kim EN, Kim DY et al. Comparison of the validity of magnetic resonance imaging and positron emission tomography/computed tomography in the preoperative evaluation of patients with uterine corpus cancer. Gynecol. Oncol. 108(3), 486-492 (2008).
94. Basu S, Nair N. Relapse of cervical cancer presenting as symptoms of Collet-Sicard syndrome with metastatic subcutaneous and adrenal deposits. Lancet Oncol. 7(7), 610 (2006).
95. Alavi A, Basu S, Musto A. Molecular imaging with PET: a revolution in medicine. Leadership Medica (2007).